SIGNS – Trademark Portfolio

Entity Type: 34

SIGNS holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 14 trademarks are registered and 1 is pending. Notable registered marks include SIGNS, NOBZZZ, NOCLEG, SECURE CAT, and SECURE DOG.

Quartier Salignan

F-84400 APT

15 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

SIGNS's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (15 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does SIGNS have?

SIGNS has 15 U.S. trademarks filed with the USPTO. Of these, 14 registered, 1 pending.

What trademark classes does SIGNS file in?

SIGNS files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SIGNS's most well-known trademarks?

SIGNS's registered trademark portfolio includes well-known marks such as SIGNS, NOBZZZ, NOCLEG, SECURE CAT, and SECURE DOG. These are among 14 currently registered trademarks in the portfolio.

What is SIGNS's trademark registration success rate?

SIGNS has a 100% trademark registration rate, with 14 out of 14 resolved applications resulting in successful registration. Currently, 1 application is pending review.